Arthritis Research & Therapy jumped from 3.44 to 5.03, propelling it to rank second in the rheumatology field in only its 6th year of publication. Breast Cancer Research also increased its impact factor moving from 2.81 to 2.93, placing it on even footing with its direct competitor, Breast Cancer Research & Treatment, which was established more than 20 years ago. Critical Care moved up to 6th in its field, and now has an impact factor of 1.9.
Four journals published by BioMed Central received their first impact factors this year. Respiratory Research (5.53) comes in from nowhere to immediately take second place in the respiratory field. Current Controlled Trials in Cardiovascular Medicine has an impact factor of 3.12. BMC Cell Biology (2.61) and BMC Health Services Research (0.67) also entered well. BioMed Central saw its impact factors go up across the board. BMC Cancer now has an impact factor of 1.7, while BMC Infectious Diseases (1.25) and BMC Public Health (0.93) also saw increases in their impact factors from the 2002 Journal Citation Report.
The impact factors, which are calculated by ISI, look at articles published in the journals in the period 2001-2002. To BioMed Central, the excellent performance of its titles answers spurious accusations of low quality of Open Access journals by some traditional subscriptions publishers.
Jan Velterop, BioMed Central's Publisher, said:
"It is becoming ever clearer that BioMed Central's Open Access journals, once beyond their early infancy, are recognised as superior to their subscription-based competitors w
'"/>
Contact: Grace Baynes
press@biomedcentral.com
44-207-631-9988
BioMed Central
25-Jun-2004